Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

J&J Longs For Cypher Longevity, May Enjoy 15-Month Monopoly In Japan

This article was originally published in The Gray Sheet

Executive Summary

Cordis aims to expand the U.S. shelf life of its Cypher sirolimus-eluting stent after resolving manufacturing issues cited by FDA in an April 2004 warning letter

You may also be interested in...



Paris Course On Revascularization In Brief

Enter CoStar: Cobalt-chromium paclitaxel-eluting stent is associated with 2.9% target lesion revascularization (TLR) rate and 7.6% major adverse event rate in 12-month follow-up results of 145-patient EuroSTAR trial, presented by Keith Dawkins, MD, Southampton University Hospital, England. The firm recently launched the 1,700-patient, 90-site COSTAR-II pivotal study. The non-inferiority trial compares CoStar with Boston Scientific's Taxus (1"The Gray Sheet" May 16, 2005, p. 17)...

Paris Course On Revascularization In Brief

Enter CoStar: Cobalt-chromium paclitaxel-eluting stent is associated with 2.9% target lesion revascularization (TLR) rate and 7.6% major adverse event rate in 12-month follow-up results of 145-patient EuroSTAR trial, presented by Keith Dawkins, MD, Southampton University Hospital, England. The firm recently launched the 1,700-patient, 90-site COSTAR-II pivotal study. The non-inferiority trial compares CoStar with Boston Scientific's Taxus (1"The Gray Sheet" May 16, 2005, p. 17)...

Boston Scientific, J&J Dwell In Separate REALITY; Data Swamps ACC

Johnson & Johnson is emphasizing Cypher's low thrombosis rates after the sirolimus-eluting stent failed to show clinical superiority over Boston Scientific's Taxus

Related Content

UsernamePublicRestriction

Register

MT021985

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel